Close menu

September 22nd, 2022 | 11:58 CEST

Cardiol Therapeutics, Apple, Nel - Crisis-proof shares, despite inflation

  • Biotechnology
  • Covid19
  • Health
Photo credits:

Heart fluttering, pulse racing among investors, share prices highly volatile due to FED measures. Inflation and recessionary times are brutal for investors in the capital market. Three candidates have the potential to become profitable long-term investments: Cardiol Therapeutics, Apple and Nel. Cardiol Therapeutics fills the gap in the pharmaceutical market for the treatment of the heart disease, myocarditis. Apple is increasingly focusing on monitoring heart health, as cardiovascular disease is one of the leading causes of death in industrialized nations. In turn, these nations are struggling with extremely high energy prices. No wonder, then, that the Norwegian government is financially supporting the Company Nel to produce green hydrogen as quickly as possible...

time to read: 5 minutes | Author: Juliane Zielonka
ISIN: CARDIOL THERAPEUTICS | CA14161Y2006 , APPLE INC. | US0378331005 , NEL ASA NK-_20 | NO0010081235

Table of contents:

    Cardiol Therapeutics closes the gap in treatment for corona-related heart disease

    US President Joe Biden has officially announced the end of the Corona pandemic. New Zealand and European countries such as France, the Netherlands and Denmark have also lifted measures to protect the public. When a disease such as COVID-19 is more prevalent in a particular population, it is called an endemic. An endemic virus thus circulates permanently in the population and can cause infections. That means that infection from COVID-19 cannot be prevented, and politicians are holding back and relying on the population's own responsibility.

    Cardiovascular diseases come into focus both through the consequences of a Corona infection and the side effects of the mRNA vaccines. The latter often occurs in the form of myocarditis or pericarditis, mostly after the second dose by a vaccine from Pfizer or Moderna. Myocarditis is an inflammation of the heart muscle. Pericarditis is inflammation of the outer covering of the heart.

    Even young men under 30 years of age have been diagnosed with myocarditis during vaccination. The risk of sudden myocardial infarction is threatening in this segment of the population. Corona will remain a viral disease permanently. So, what can doctors and patients do to protect against the life-threatening consequences of myocarditis?

    Until now, acute cases have been treated with the recommended therapies for heart failure. These include diuretics, ACE inhibitors, angiotensin receptor blockers, beta blockers and aldosterone inhibitors. In severe and sudden cases, intensive treatment is often required. Currently, there is no specific treatment for acute myocarditis.

    The US-based Company Cardiol Therapeutics has set out to fill precisely this gap with its CardiolRx™ product. The novel therapeutic is a pharmaceutical cannabidiol formulation currently undergoing trial in one of the highest medically approved clinical trials.

    The anti-inflammatory effect of cannabidiol in models of cardiovascular disease is a major breakthrough in treating acute myocarditis, according to Cardiol. The abundant experimental evidence suggests that this novel therapy, in the form of the drug CardiolRx™, holds great promise and could receive orphan drug designation. Currently, the share stands at EUR 1.16.

    Apple - Latest Apple Watch operating system focuses on heart health

    Increasingly, Apple is also specializing in heart health. The iPhone's Health function only gets going together with the Apple Watch. Apple Watch users can enjoy several new, useful running features in the watchOS 9 operating system. These include Cardio Recovery, stride length and ground contact time, among others. The Cardio Recovery feature, previously found under the term "Heart Rate Recovery" on the Apple Watch, will be renamed "Cardio Recovery" with watchOS 9 and iOS 16, perhaps to align with the new Cardio Fitness metric (VO2 max) that will appear in the Health app starting with iOS 16.

    Cardio Recovery measures how quickly the heart rate drops immediately after exercise. Like heart rate recovery (HRR), heart rate variability also shows information about heart health. Heart rate is directly related to the autonomic nervous system. The activity of the resting and digestive nervous systems is an important factor in life expectancy. This is reflected by measures of parasympathetic activity, which has been shown to be a critical predictive factor for mortality.

    Cardio Recovery is also useful for people who have suffered a heart attack. Recent scientific research shows that Cardio Recovery can improve heart rate recovery by 18-22 beats per minute. Thus, Apple proves how valuable heart health data is to one's physical fitness. In connection with the innovative drug from Cardiol Therapeutics with simultaneous monitoring by, e.g. the Apple Watch under medical supervision, many lives can be healthily prolonged. Medical technology on the wrist is another step of the conglomerate in Cupertino to inspire its users.

    Nel - At high speed to green hydrogen technology

    The current energy prices for electricity and gas can also quickly come to heart rhythm disturbances. Whether as a company owner who sees his production site at risk or a private investor in an apartment with a gas supply - prices have exploded.

    Savvy investors are looking to companies of the future like Nel ASA, based in Norway. The Company specializes in the development of green hydrogen and its production facilities. Green hydrogen is essential in permanently leaving fossil fuels as an energy source. It is given the professional designation of green hydrogen only when no fossil fuel is used in its production..

    Water electrolysis is a key technology for Nel to convert renewable energy into hydrogen and has excellent growth potential. Factors driving growth are reduction in capital expenditures and operating costs. This can be achieved through improvements in product design, catalysts, membranes and optimization of operating conditions.

    Currently, the review and validation of design changes is a lengthy process that includes long-term durability testing. New protocols for accelerated stress testing will help speed Nel's validation of new materials and cells. This, in turn, will reduce technical product risk and enable the faster introduction of new materials into Nel's commercial electrolyzers.

    Nel and the Norwegian Institute for Energy Technology (IFE) have received an injection of EUR 1.2 billion from the Norwegian Research Council to accelerate their testing procedures. The objective is to shorten the time until new green hydrogen technologies can be brought to market. Nel's share price, similar to Cardiol Therapeutics, is currently trading at EUR 1.19.

    Many countries are allowing the Corona pandemic to become endemic. Personal responsibility is required from everyone. Heart muscle inflammation or heart disease has increased sharply in the last two years with or without vaccination. Cardiol Therapeutics has a promising drug coming to market that may fill the current gap in treating acute myocarditis. Those who have questions for CEO David Elsley about this will have the opportunity to ask them live on September 27 at the virtual II-Forum. Click here to register for free. Its efficacy is currently being researched in clinical studies according to the highest medical standards. Apple is also increasingly focusing on heart health, enabling its Apple Watch users to gain data sovereignty over their heart rate. Cardiovascular disease is one of the highest causes of death in developed countries. Apple is already in the B2B medical space. The wearable heart computer on the wrist of its B2C users opens up another immeasurable pool of data that could be future-oriented for the development of the Californian company. The Norwegian company Nel is also looking to the future. With a government grant of EUR 1.2 billion, the Company's researchers and engineers are doing everything possible to shorten the development cycles for green hydrogen.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author

    Related comments:

    Commented by Nico Popp on September 27th, 2023 | 07:10 CEST

    Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics

    • Biotechnology
    • Pharma

    High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!


    Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST

    Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets

    • Biotechnology
    • Pharma
    • Electromobility

    Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.


    Commented by André Will-Laudien on September 18th, 2023 | 06:30 CEST

    Unbelievable! Hands off AI, biotech in rebound! Bayer, Defence Therapeutics, Morphosys

    • AI
    • Biotechnology
    • Investments

    The big fall decline is now over. It is always a difficult time, but the so-called "Triple Witching" went relatively smoothly this time. The European Central Bank (ECB), in its first interest rate meeting after the summer break, decided to raise key rates by another quarter point to 4.00%, up from the previous 3.75% in July. At the same time, it lowered its inflation forecast for 2025 and the outlook for economic growth in the Eurozone for the years 2023 to 2025. Economic risks are increasing, but inflation remains the determining factor for interest rates. Expectations that the US Federal Reserve (FED) will announce an interest rate pause at its next meeting on Wednesday have boosted confidence. Last week's big losers were the recently favoured AI stocks Nvidia, Microsoft and However, the biotech sector has recently started to climb again. Where are the opportunities for investors?